Shares of this digital medical platform were up more than 100% at one point. Here's what's driving it

Doximity shares surged 130% (and more than doubled intraday) after CEO Jeffrey Tangney said its new AI search tool generates >10x in revenue versus runtime costs, with unit economics expected to improve as models become more efficient. Financially, Q1 FY27 revenue rose to $156.6M and adjusted EBITDA to $74.8M, both above consensus, and full-year revenue guidance was raised by $6M (+5%) to $671M–$681M—though analysts view the AI profitability upside as not fully reflected in the forecast. The move also appears amplified by positioning: ~17% of float was short heading into results, setting up a likely squeeze as shorts unwind.

Analysis

This is less a clean earnings beat than a repricing of DOCS as a monetizable distribution asset with embedded AI optionality. The near-term move can persist because 17% short interest creates mechanical demand, but that is a flow event, not proof of a step-change in intrinsic value. The real valuation question is whether AI search becomes a durable high-margin revenue line or just a high-ARPU experiment layered onto an already healthy core.

Second-order winners are pharma and med-tech advertisers that gain a more targeted channel, plus any healthcare SaaS names with authenticated user graphs and direct monetization rights. The losers are generic digital ad intermediaries and any healthcare marketing platform that lacks proprietary clinician identity; if DOCS proves that precision inventory can command premium economics, budget share may migrate away from broad search and general-purpose adtech. The competitive moat is not the AI model itself, but the first-party healthcare graph and workflow integration.

The main risk is timing mismatch: the market may be capitalizing 6-18 months of upside before management has to prove it in reported revenue. If AI search contribution does not show up in revenue per user, gross margin, or a bigger FY27 guide over the next 1-2 quarters, the stock can give back a large chunk once squeeze pressure fades. Consensus may be missing the long-term platform value, but the immediate move is probably ahead of the data.

Key Decisions for Investors

• Cover any DOCS short exposure into the squeeze; short interest is now a tactical liability for the next 1-3 weeks, not an edge.
• For new longs, wait for 3-5 trading days of consolidation and only add if DOCS holds above the post-gap support zone; chase risk is high after a sentiment-driven re-rate.
• Express upside cautiously with a 3-6 month DOCS call spread on a pullback, rather than outright stock, to participate in AI optionality while limiting decay if the monetization story stalls.
• Set a catalyst alert for the next quarterly call: if management still cannot quantify AI search contribution in revenue or margin terms, fade the move and consider a short against strength.
• Relative-value idea: long DOCS versus a weaker digital-health monetization name on any broad healthcare selloff, but keep sizing modest until the AI revenue stream is independently visible.